Board of Directors

The Company Directors of Sphere Fluidics are world leaders in the development of cell-based and picodroplet technologies and systems. Each has a proven track record in creating and building successful biotechnology and instrumentation businesses, and many have significant technical know-how. Thanks to the diverse range of their individual experiences, the Board has a comprehensive understanding of the drivers, trends and opportunities presented by the Life Sciences marketplace.
Dr Andrew Mackintosh

Dr Andrew Mackintosh

Chairman and Company Director

Dr Mackintosh was previously the Chief Executive of the Royal Society Enterprise Fund, UK Academy of Sciences (the oldest science organisation in the world). The Enterprise Fund was an early-stage technology investment fund backed in a novel way by philanthropy, built to utilise the unique brand, assets and networks of the Royal Society to optimise investment decisions. The Fund invested in start-up companies based on excellent science and exhibiting outstanding commercial potential.

Andrew has over 25 years of commercial and general management experience in publicly- and privately-owned international technology companies. He has been the CEO of spin-out companies from both the University of Oxford and University of Cambridge, including Oxford Instruments PLC (from 1998-2005), the first-ever spin-out from Oxford University.

Andrew has a PhD in Physics from the University of Cambridge and is a Fellow of the Institute of Physics and of the Institute of Directors. He has served on numerous national and regional committees concerned with technical innovation and competitiveness, and is currently on the Board of Directors of several start-ups.

Dr Frank F. Craig MBA

Dr Frank F. Craig MBA

CEO and Company Director

Dr Craig has amassed around 20 years of management experience while working for large, internationally renowned life sciences companies and start-ups alike, including GlaxoSmithKline and Amersham Biosciences (which later merged to form GE Healthcare Life Sciences). He has managed the product development and commercialisation of a number of cell-based products, systems and services across the life science industry, including Green Fluorescent Protein, which was first identified by the 2008 Nobel Prize Winners for Chemistry.

Frank was a co-Founder and CEO of Smart Holograms (Cambridge, UK) as well as a co-Founder and Vice-President of Aurora Biosciences (San Diego, USA), which had a peak market capitalisation of £1.8 billion and was acquired by Vertex Pharmaceuticals for £420 million.

Frank has delivered many commercial partnerships with global Life Sciences firms, resulting in recorded deal values of £180 million. He has also raised around £30 million in Angel and Venture Capital investment and £25 million via an IPO on NASDAQ. He helped form Sphere Fluidics before becoming its CEO in May 2010 and he is now also President of Sphere Fluidics Incorporated.

Mr Ian Gray

Mr Ian Gray

Company Director

Mr Gray is a representative of 24Haymarket, an investment group based in London, whose members have an average of 30 years’ experience in the Private Equity industry. Prior to this role, Ian was the Managing Director of Candover, where he led various investments into companies including: Clondalkin, Ontec, Bourne Leisure, Innovia, Wood Mackenzie, Dx Group, Ferretti and Inveresk Research. With the latter, Ian was involved from its start-up phase through to its eventual Trade Sale for £600 million.

He was also previously the Head of Structured Finance (UK and Europe) at the Bank of Scotland and held other financial roles at TSB and Arthur Andersen during earlier phases of his career. Ian is a Chartered Accountant and has a B. Com (Hons) in Business Studies and Law from Edinburgh University.

Dr Amanda Wooding

Dr Amanda Wooding

Company Director

Dr Wooding joined Cambridge Enterprise in January 2009 as a Technology Manager in the Life Sciences Team and is now Deputy Head of its Life Sciences function. Before joining Cambridge Enterprise, she gained over ten years of experience in technology commercialisation from roles within The Wellcome Trust, the commercialisation company Catalyst Biomedica and at Acambis. As the UK-based Director of Business Development at Acambis, she was responsible for in- and out-licensing, most notably securing a Phase III out-licensing deal with Sanofi Pasteur. While at the Wellcome Trust, she served as the Catalyst/Wellcome Trust observer to the Board for three start-up biotechnology companies.

Amanda has a PhD in molecular endocrinology from the University of Cambridge and enjoyed post-doctoral research positions both at Cambridge and in industry.